Literature DB >> 25970141

Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma.

S Mourah1, R Porcher2, M Battistella3, D Kerob4, B Guillot5, T Jouary6, F Agbalika7, F Morinet8, V Furlan9, H M Teisserenc10, N Dupin11, C Lebbé4,12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25970141     DOI： 10.1111/bjd.13897

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

Review 1.  Post-transplantation malignancies: here today, gone tomorrow?

Authors:  Edward K Geissler
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

2.  Everolimus-Induced Remission of Classic Kaposi's Sarcoma Secondary to Cryptic Splicing Mediated CTLA4 Haploinsufficiency.

Authors:  Jin Yan Yap; Brian Gloss; Marcel Batten; Peter Hsu; Lucinda Berglund; Fenfen Cai; Pei Dai; Andrew Parker; Min Qiu; Wendell Miley; Romin Roshan; Vickie Marshall; Denise Whitby; Eric Wegman; Roger Garsia; Kathy H C Wu; Edwin Kirk; Mark Polizzotto; Elissa K Deenick; Stuart G Tangye; Cindy S Ma; Tri Giang Phan
Journal:  J Clin Immunol       Date:  2020-06-19       Impact factor: 8.317

Review 3.  Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update.

Authors:  Hallvard Holdaas; Paolo De Simone; Andreas Zuckermann
Journal:  J Transplant       Date:  2016-10-11

Review 4.  Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.

Authors:  Marc-Antoine Valantin; Léna Royston; Maxime Hentzien; Aude Jary; Alain Makinson; Marianne Veyri; Sylvie Ronot-Bregigeon; Stéphane Isnard; Romain Palich; Jean-Pierre Routy
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.